Is vivo stock a good buy?
Is vivo stock a good buy?
Our proprietary system currently recommends Meridian Bioscience (VIVO) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.
Who owns Vivo stock?
Top 10 Owners of Meridian Bioscience Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 14.89% | 6,450,059 |
| The Vanguard Group, Inc. | 11.36% | 4,923,782 |
| EARNEST Partners LLC | 10.02% | 4,341,834 |
| Royce & Associates LP | 4.71% | 2,042,499 |
Why did InVivo Therapeutics price drop?
Shares of InVivo Therapeutics $NVIV tanked this morning after the Cambridge, MA-based biotech said it halted enrollment in its lead INSPIRE study after the third patient treated with its spinal cord implant died. InVivo shares plunged more than 30%.
What is VIVO phone?
Last Updated: 28th August 2021. Vivo Electronics Corp. is a phone brand based in Dongguan, Guangdong, China. It was founded in 2009. The company is another Chinese smartphone maker to enter India recently. It makes low-cost Android phones, and those in the mid-range segment of the market.
What does Meridian Bioscience do?
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components.
Will InVivo Therapeutics stock go up?
The InVivo Therapeutics Holdings Corp. stock price gained 2.70% on the last trading day (Friday, 27th Aug 2021), rising from $0.65 to $0.67. The price has been going up and down for this period, and there has been a 11.64% gain for the last 2 weeks.
What does InVivo Therapeutics do?
At InVivo, we are focused on redefining the treatment of spinal cord injury. At InVivo, we are focused on redefining the treatment of spinal cord injury. By modulating the healing environment to facilitate cell survival and growth, we have the opportunity to change the treatment of spinal cord injury.
How many employees does Meridian Bioscience have?
550 employees
Meridian Bioscience has 550 employees.
Where is Meridian Bioscience located?
Cincinnati, OH
Meridian is headquartered in Cincinnati, OH, and has offices in eight countries and employs more than 600 people.
Is Atossa a buy?
Atossa Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
What was the stock price of VIVO Cannabis?
VIVO Cannabis’ stock was trading at $0.1620 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VVCIF stock has decreased by 9.7% and is now trading at $0.1463. View which stocks have been most impacted by Coronavirus.
What is the stock price of InVivo Therapeutics?
InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 7,000,000 shares of its common stock, par value $0.00001 per share, at a price to the public of $0.12 per share. H.C. Wainwright & Co. is acting as exclusive placement agent in connection with the offering.
What kind of stock is Meridian Bioscience ( vivo )?
Has Meridian Bioscience (VIVO) Outpaced Other Medical Stocks This Year? NuVasive (NUVA) Hits a New 52-Week High: What’s Driving It? Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products.
Who are the Institutional Buyers of vivo stock?
VIVO stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Renaissance Technologies LLC, Prudential Financial Inc., Acadian Asset Management LLC, Grantham Mayo Van Otterloo & Co. LLC, Millennium Management LLC, JPMorgan Chase & Co., and Dimensional Fund Advisors LP.
https://www.youtube.com/watch?v=JmrkulF3eO8